- Home
- INCR vs CNTX Comparison
INCR vs CNTX Comparison
Compare INCR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- CNTX
- Stock Information
- Founded
- INCR 1994
- CNTX 2015
- Country
- INCR Israel
- CNTX United States
- Employees
- INCR N/A
- CNTX N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- INCR Health Care
- CNTX Health Care
- Exchange
- INCR Nasdaq
- CNTX Nasdaq
- Market Cap
- INCR 76.7M
- CNTX 78.0M
- IPO Year
- INCR N/A
- CNTX 2021
- Fundamental
- Price
- INCR $1.58
- CNTX $0.58
- Analyst Decision
- INCR
- CNTX Strong Buy
- Analyst Count
- INCR 0
- CNTX 4
- Target Price
- INCR N/A
- CNTX $6.00
- AVG Volume (30 Days)
- INCR 8.6K
- CNTX 164.6K
- Earning Date
- INCR 05-01-2025
- CNTX 05-07-2025
- Dividend Yield
- INCR N/A
- CNTX N/A
- EPS Growth
- INCR N/A
- CNTX N/A
- EPS
- INCR N/A
- CNTX N/A
- Revenue
- INCR $65,575,323.00
- CNTX N/A
- Revenue This Year
- INCR $69.54
- CNTX N/A
- Revenue Next Year
- INCR $41.75
- CNTX N/A
- P/E Ratio
- INCR N/A
- CNTX N/A
- Revenue Growth
- INCR N/A
- CNTX N/A
- 52 Week Low
- INCR $1.17
- CNTX $0.49
- 52 Week High
- INCR $3.28
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- INCR 55.03
- CNTX 33.91
- Support Level
- INCR $1.51
- CNTX $0.49
- Resistance Level
- INCR $1.59
- CNTX $0.71
- Average True Range (ATR)
- INCR 0.05
- CNTX 0.08
- MACD
- INCR -0.00
- CNTX -0.02
- Stochastic Oscillator
- INCR 55.63
- CNTX 33.31
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.